Arcus Biosciences Target Price

Where could RCUS trade next? Consensus target price: $39.

Get informed when a big investor buys or sells

+ Follow

Share Price

$28.62

Average Target Price

$39.00

36.3% upside

6 analysts in the last 4 months

High: $47 | Low: $22

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-07	Goldman SachsRichard Law	$42	46.8% upside
2026-08-06	Wedbush	$43	50.2% upside
2026-07-20	H.C. WainwrightEmily Bodnar	$45	57.2% upside
2026-05-18	Truist Financial	$35	22.3% upside
2026-05-11	Morgan Stanley	$22	23.1% downside
2026-04-20	Leerink Partners	$47	64.2% upside
2026-02-12	Wells Fargo	$23	19.6% downside
2026-01-12	Goldman SachsRichard Law	$28	2.2% downside
2026-01-08	Morgan Stanley	$20	30.1% downside
2025-12-12	Truist Financial	$30	4.8% upside
2025-12-12	H.C. Wainwright	$32	11.8% upside
2025-10-30	Goldman SachsSalveen Richter	$16	44.1% downside
2025-10-29	Wedbush	$35	22.3% upside
2025-10-29	H.C. Wainwright	$28	2.2% downside
2025-10-07	Truist FinancialAsthika Goonewardene	$39	36.3% upside
2025-05-07	Wells FargoEva Fortea Verdejo	$26	9.2% downside
2024-10-24	CitigroupYigal Nochomovitz	$46	60.7% upside
2024-10-21	H.C. WainwrightEmily Bodnar	$20	30.1% downside
2024-10-08	Wells FargoEva Fortea Verdejo	$29	1.3% upside
2024-10-08	Morgan StanleyJudah Frommer	$35	22.3% upside
2024-08-09	Bank of America SecuritiesJason Zemansky	$23	19.6% downside
2024-07-08	BarclaysPeter Lawson	$25	12.6% downside
2024-06-24	Truist FinancialAsthika Goonewardene	$44	53.7% upside
2024-06-04	BarclaysPeter Lawson	$35	22.3% upside
2022-12-20	Citigroup	$42	46.8% upside
2022-11-23	Citigroup	$37	29.3% upside
2022-05-11	WedbushRobert Driscoll	$42	46.8% upside

Arcus Biosciences (RCUS) FAQ

Arcus Biosciences's target price stands at $39. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $39 for RCUS implies 36.3% upside versus today's price ($28.62). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Arcus Biosciences's target price evolved across reporting periods, while the comparison chart places RCUS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Arcus Biosciences's reading of $39 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.